EMT6 Syngeneic Model Overview
The EMT6 syngeneic model is a well-established murine mammary carcinoma system derived from a spontaneous breast tumor in BALB/c mice. This model has been widely employed in preclinical oncology for over four decades and remains one of the most frequently used syngeneic breast cancer models for immunotherapy and radiation research. EMT6 tumors exhibit moderately aggressive growth, a stable epithelial phenotype, and the ability to grow in fully immunocompetent hosts, allowing detailed investigation of tumor-immune interactions, immune escape mechanisms, and therapeutic modulation within an intact immune system.
When implanted orthotopically or subcutaneously in BALB/c mice, EMT6 cells generate rapidly growing, vascularized tumors that maintain a relatively low rate of spontaneous metastasis. This combination of robust growth kinetics and contained disease spread provides a controlled environment for evaluating immune checkpoint inhibitors, chemotherapeutic agents, and radiotherapy combinations. The EMT6 model is particularly valuable for mechanistic studies focusing on immune memory formation, radiation-induced immune modulation, and tumor microenvironment remodeling following therapy.
Request a Custom Quote for EMT6 Syngeneic ModelBiological and Molecular Characteristics
The EMT6 cell line was derived from a spontaneous mammary carcinoma in BALB/c mice and retains an epithelial morphology with well-defined cell–cell junctions. It lacks expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, representing a murine equivalent of triple-negative breast cancer. EMT6 tumors are characterized by a balanced immune microenvironment containing both cytotoxic lymphocytes and suppressive myeloid populations, providing an ideal context for evaluating immune-modulatory therapies.
The molecular profile of EMT6 includes moderate expression of matrix metalloproteinases (MMP-2 and MMP-9) and vascular endothelial growth factor (VEGF), supporting angiogenesis and local invasiveness. The model also expresses interferon-stimulated genes and cytokines such as CXCL9, CXCL10, and IL-6, which regulate immune cell recruitment and contribute to tumor-immune equilibrium. The immune landscape of EMT6 is dynamic and responsive to therapy, making it highly suitable for investigations into the adaptive immune response to both local and systemic treatments.
| Parameter | Description |
|---|---|
| Host strain | BALB/c (female, 6–8 weeks) |
| Tumor origin | Spontaneous mammary carcinoma (mouse) |
| Receptor status | ER– / PR– / HER2– |
| Inoculation route | Orthotopic (mammary fat pad) or subcutaneous |
| Tumor take rate | >95% |
| Doubling time | Approximately 3–4 days in vivo |
| Metastatic potential | Low; occasional lung micrometastases |
| Immunophenotype | Mixed lymphoid and myeloid infiltration |
| Common applications | Immunotherapy, radiotherapy, combination treatment studies |
In Vivo Model Development and Tumorigenicity
In vivo establishment of the EMT6 syngeneic model is typically achieved through orthotopic or subcutaneous implantation of viable tumor cells into BALB/c mice. Tumors generally become palpable within one week and demonstrate reproducible growth with a high take rate. The subcutaneous model variant is particularly useful for tumor volume monitoring and noninvasive imaging, while the orthotopic model provides a physiologically relevant setting for evaluating local invasion, vascularization, and immune infiltration.
Although EMT6 tumors exhibit rapid local expansion, they rarely form extensive spontaneous metastases, allowing extended study durations and repeated therapeutic interventions within a single animal. This makes the model suitable for comparative analyses of radiation-induced immune modulation, chemotherapy-induced immunogenic cell death, and adaptive immune priming following immunotherapy. The model’s predictability and reproducibility have contributed to its long-standing use in evaluating novel therapeutic strategies under immune-competent conditions.
Request a Custom Quote for EMT6 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological examination reveals that EMT6 tumors consist of cohesive epithelial sheets with moderate pleomorphism, organized vasculature, and limited necrosis. The tumors exhibit variable stromal density, containing fibroblasts, macrophages, and lymphocytes interspersed throughout the extracellular matrix. The vasculature is well-developed but irregular, supporting rapid proliferation and oxygen diffusion.
Immunohistochemical analysis demonstrates strong Ki-67 staining indicative of high proliferative activity. PD-L1 is expressed on both tumor and immune cells, while CD3 and CD8 staining identify abundant T-cell infiltration throughout the tumor parenchyma and periphery. F4/80 staining reveals a prominent macrophage population, with a balanced distribution of M1 and M2 phenotypes depending on treatment context. EMT6 tumors often display variable MHC class I expression, reflecting immune editing under selective pressure during tumor progression. The histological and immunohistochemical profile of EMT6 closely parallels that of human triple-negative breast cancers with an immune-infiltrated phenotype.
Preclinical Applications and Drug Response
The EMT6 model has been extensively employed in preclinical oncology to evaluate immune checkpoint blockade, combination immunotherapy, radiotherapy, and chemotherapeutic regimens. Anti-PD-1 and anti-CTLA-4 antibodies elicit partial tumor regression and prolonged survival in this model, often accompanied by enhanced CD8⁺ T-cell infiltration and increased interferon-γ signaling. The model is also used to explore synergistic effects of radiation combined with immunotherapy, demonstrating radiation-induced immunogenic cell death and improved T-cell priming when checkpoint blockade is administered concurrently.
Chemotherapeutic agents such as cyclophosphamide, doxorubicin, and paclitaxel have shown variable efficacy depending on dosing regimen and timing relative to immune activation. EMT6’s responsiveness to both immune and cytotoxic agents makes it an ideal system for mechanistic studies of therapeutic synergy, immune reprogramming, and tumor microenvironment remodeling. Owing to its reproducibility, balanced immune profile, and moderate aggressiveness, EMT6 remains a foundational model for the evaluation of new immunotherapeutic and combined-modality treatment strategies in breast cancer research.
Request This Model
To request the EMT6 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for EMT6 Syngeneic Model